Core Discrete Event Simulation Model for the Evaluation of Health Care Technologies in Major Depressive Disorder

被引:11
|
作者
Vataire, Anne-Lise [1 ]
Aballea, Samuel [1 ]
Antonanzas, Fernando [2 ]
Hakkaart-van Roijen, Leona [3 ]
Lam, Raymond W. [4 ]
McCrone, Paul [5 ]
Persson, Ulf [6 ]
Toumi, Mondher [7 ]
机构
[1] Creat Ceut, F-75008 Paris, France
[2] Univ La Rioja, Logrono, Spain
[3] Erasmus Univ, Rotterdam, Netherlands
[4] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
[5] Kings Coll London, London, England
[6] Swedish Inst Hlth Econ, Lund, Sweden
[7] Univ Lyon, Lyon, France
关键词
antidepressants; cost-effectiveness; depression; discrete event simulation; RESIDUAL SYMPTOMS; IMPACT; REMISSION; CITALOPRAM; COSTS; RISK;
D O I
10.1016/j.jval.2013.11.012
中图分类号
F [经济];
学科分类号
02 ;
摘要
Objective: A review of existing economic models in major depressive disorder (MDD) highlighted the need for models with longer time horizons that also account for heterogeneity in treatment pathways between patients. A core discrete event simulation model was developed to estimate health and cost outcomes associated with alternative treatment strategies. Methods: This model simulated short- and long-term clinical events (partial response, remission, relapse, recovery, and recurrence), adverse events, and treatment changes (titration, switch, addition, and discontinuation) over up to 5 years. Several treatment pathways were defined on the basis of fictitious antidepressants with three levels of efficacy, tolerability, and price (low, medium, and high) from first line to third line. The model was populated with input data from the literature for the UK setting. Model outputs include time in different health states, quality-adjusted life-years (QALYs), and costs from National Health Service and societal perspectives. The codes are open source. Results: Predicted costs and QALYs from this model are within the range of results from previous economic evaluations. The largest cost components from the payer perspective were physician visits and hospitalizations. Key parameters driving the predicted costs and QALYs were utility values, effectiveness, and frequency of physician visits. Differences in QALYs and costs between two strategies with different effectiveness increased approximately twofold when the time horizon increased from 1 to 5 years. Conclusion: The discrete event simulation model can provide a more comprehensive evaluation of different therapeutic options in MDD, compared with existing Markov models, and can be used to compare a wide range of health care technologies in various groups of patients with MUD.
引用
收藏
页码:183 / 195
页数:13
相关论文
共 50 条
  • [41] Developing and testing a discrete event simulation model to evaluate budget impacts of diabetes prevention programs
    Kaasalainen, Karoliina
    Kalmari, Janne
    Ruohonen, Toni
    JOURNAL OF BIOMEDICAL INFORMATICS, 2020, 111
  • [42] Core antibiotic resistance genes mediate gut microbiota to intervene in the treatment of major depressive disorder
    Dong, Zaiquan
    Han, Ke
    Xie, Qinglian
    Lin, Chunting
    Shen, Xiaoling
    Hao, Yanni
    Li, Jin
    Xu, Haizhen
    He, Lin
    Yu, Tao
    Kuang, Weihong
    JOURNAL OF AFFECTIVE DISORDERS, 2024, 363 : 507 - 519
  • [43] INTRODUCTION OF RFID TECHNOLOGIES IN A MANUFACTURING SYSTEM A Discrete Event Simulation Approach
    Haouari, Lobna
    Absi, Nabil
    Feillet, Dominique
    SIMULTECH 2011: PROCEEDINGS OF THE 1ST INTERNATIONAL CONFERENCE ON SIMULATION AND MODELING METHODOLOGIES, TECHNOLOGIES AND APPLICATIONS, 2011, : 523 - 529
  • [44] Discrete event simulation in the health policy and management program
    Groothuis, S
    van Merode, GG
    METHODS OF INFORMATION IN MEDICINE, 2000, 39 (4-5) : 339 - 342
  • [45] Towards a multimethodology in health care synergies between Soft Systems Methodology and Discrete Event Simulation
    Holm, Lene Berge
    Dahl, Fredrik A.
    Barra, Mathias
    HEALTH SYSTEMS, 2013, 2 (01) : 11 - 23
  • [46] Predictors of engagement with remote sensing technologies for symptom measurement in Major Depressive Disorder
    Matcham, F.
    Carr, E.
    White, K. M.
    Leightley, D.
    Lamers, F.
    Siddi, S.
    Annas, P.
    De Girolamo, G.
    Haro, J. M.
    Horsfall, M.
    Ivan, A.
    Lavelle, G.
    Li, Q.
    Lombardini, F.
    Mohr, D. C.
    Narayan, V. A.
    Penninx, B. W. H. J.
    Oetzmann, C.
    Coromina, M.
    Simblett, S. K.
    Weyer, J.
    Wykes, T.
    Zorbas, S.
    Brasen, J. C.
    Myin-Germeys, I.
    Conde, P.
    Dobson, R. J. B.
    Folarin, A. A.
    Ranjan, Y.
    Rashid, Z.
    Cummins, N.
    Dineley, J.
    Vairavan, S.
    Hotopf, M.
    JOURNAL OF AFFECTIVE DISORDERS, 2022, 310 : 106 - 115
  • [47] Clinical Neuropsychological Evaluation in Older Adults With Major Depressive Disorder
    McClintock, Shawn M.
    Minto, Lex
    Denney, David A.
    Bailey, K. Chase
    Cullum, C. Munro
    Dotson, Vonetta M.
    CURRENT PSYCHIATRY REPORTS, 2021, 23 (09)
  • [48] Economic evaluation of desvenlafaxine in the treatment of major depressive disorder in Spain
    Rejas Gutierrez, Javier
    Blanca Tamayo, Milagrosa
    Gascon Barrachina, Josep
    Armada Pelaez, Beatriz
    REVISTA DE PSIQUIATRIA Y SALUD MENTAL, 2016, 9 (02): : 87 - 96
  • [49] Clinical Neuropsychological Evaluation in Older Adults With Major Depressive Disorder
    Shawn M. McClintock
    Lex Minto
    David A. Denney
    K. Chase Bailey
    C. Munro Cullum
    Vonetta M. Dotson
    Current Psychiatry Reports, 2021, 23
  • [50] PERFORMANCE EVALUATION OF HEALTH INFORMATION SYSTEMS USING ARIS MODELING AND DISCRETE-EVENT SIMULATION
    Augusto, Vincent
    Rejeb, Olfa
    Xie, Xiaolan
    Aloui, Saber
    Perrier, Lionel
    Biron, Pierre
    Durand, Thierry
    2015 WINTER SIMULATION CONFERENCE (WSC), 2015, : 1503 - 1514